What is the purpose of target validation in drug development?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

What is the purpose of target validation in drug development?

Target validation asks whether modulating a biological target will yield a therapeutic benefit in the disease context. It provides evidence that the target is causally linked to disease progression and that engaging it with a modulator leads to a measurable, beneficial effect in relevant models. This often comes from genetic data (loss- or gain-of-function studies and human genetic associations) and pharmacological data (showing that selective modulation changes disease-related readouts in cells, animals, or ex vivo systems). Validation helps de-risk the program by demonstrating that altering the target can meaningfully impact disease biology and that the effects are potentially translatable to patients, often guiding biomarker development and patient selection for trials. Identifying a genetic sequence is an early discovery step, not validation of therapeutic relevance. Marketability is a business consideration, not the biological justification for pursuing a target. Formulation feasibility concerns drug delivery and stability, not whether the target modulates disease biology.

Target validation asks whether modulating a biological target will yield a therapeutic benefit in the disease context. It provides evidence that the target is causally linked to disease progression and that engaging it with a modulator leads to a measurable, beneficial effect in relevant models. This often comes from genetic data (loss- or gain-of-function studies and human genetic associations) and pharmacological data (showing that selective modulation changes disease-related readouts in cells, animals, or ex vivo systems). Validation helps de-risk the program by demonstrating that altering the target can meaningfully impact disease biology and that the effects are potentially translatable to patients, often guiding biomarker development and patient selection for trials.

Identifying a genetic sequence is an early discovery step, not validation of therapeutic relevance. Marketability is a business consideration, not the biological justification for pursuing a target. Formulation feasibility concerns drug delivery and stability, not whether the target modulates disease biology.

More practice questions